Pfizer Inc. and Mylan Inc. will lower the prices on medicines for patients with drug-resistant HIV and they will be available to governments that are members of the William J. Clinton Foundation"s Procurement Consortium in Africa, Asia, Latin America and the Caribbean. Pfizer will cut the price of its tuberculosis drug, Mycobutin (rifabutin) by 60 percent for patients taking second-line antiretroviral therapies for HIV/AIDS. While Mylan will cut the price of its second-line antiretroviral treatments from $475 to $425 per year. The four drugs atazanavir, ritonavir, tenofovir and lamivudine, will be combined into three with tenofovir and lamivudine combined into a single pill. In his announcement of the deal Clinton has said that the drugs would be even more important in coming years, as more people become resistant to the first line of treatment drugs.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지